SAGE Centers is focused on providing outstanding patient care. We also participate in clinical trials designed to find new treatments, and we share information about clinical trials our partners are leading.
Please check this page for clinical trial posts. You may also follow us on Facebook, LinkedIn, Twitter and Instagram to receive updates.
ImpriMed and SAGE
Improving Future Care for Lymphoma Patients
SAGE invites you and your dog to participate in our long-term research study with ImpriMed, a Palo Alto-based company headed by researchers trained at Stanford University. ImpriMed creates personalized drug combinations to combat cancer and infectious diseases. With pet owners’ consent, SAGE collects canine lymphoma cells with a non-invasive fine-needle aspirate and gives them to ImpriMed to test different chemotherapeutic drugs and concentrations. While there is no immediate health benefit to your pet, voluntarily donating their cells advances veterinary medicine and gives scientists more opportunities to test drugs and drug combinations that could help pets with cancer in the future. There is no cost to participate in this research study. Your SAGE oncologist will extract the cells during your pet’s regular visit. Speak to your SAGE doctor to learn more about how you and your pet can help advance treatment options for dogs with lymphoma.
Clinical Trials and Research: How PetCure Oncology is Advancing Cancer Care for Pets
PetCure Oncology is on a mission to revolutionize pet cancer care with stereotactic radiation (SRS/SRT), an advanced form of radiation therapy that has been proven effective in humans. To date, we’ve seen SRS/SRT treat many different types of pet cancers in more than 2,500 patients—and our specialists are determined to understand the safety and benefits of SRS/SRT on all tumors.
Whether you’re a pet parent or veterinarian, you may be able to take part in a clinical trial we’re currently conducting. Please see below for more information.
PetCure Blood Cell Evaluation Trial: https://petcureoncology.com/clinicaltrials/
SAGE & The Hemangiosarcoma Study
Has your dog been diagnosed with hemangiosarcoma? This is a serious and deadly cancer that invades the blood vessels. You may wish to consider enrolling your pet in a clinical study coordinated by Iowa State University. Researchers will be assessing the benefit of an immunotherapy in combination with chemotherapy after surgery to see if your dog’s overall survival time can be extended. You will receive $60 per visit toward treatment costs.
SAGE Direct Test by SageMedic Corp
Predicting the Right Treatment for the Right Patient
Every tumor is different and therefore it has been difficult to predict which therapy is likely to be most effective. The development of next generation sequencing has enabled oncologists to get a better understanding of the underlying genomic mutation and mechanism of an individual cancer. Unfortunately, in the vast majority of cases, a relevant mutation cannot be identified and as of today it is not possible to accurately predict the most effective therapy.
However, the goal of the collaboration between SageMedic Corp. and SAGE Veterinary Centers is to change that. SageMedic Corp. has developed the SAGE Direct Test™ and here is how it works. A patient’s live tumor biopsy will be taken to create in-vitro hundreds of 3D-microtumors that are similar to the patient’s original tumor. Those live, in-vitro microtumors will then be exposed to various treatment options and within less than a week, SageMedic will be able to identify the most effective therapy. We are excited to expand our SAGE Direct Test™ to the veterinarian practice in order to improve the lives of beloved pets and their owners once our development is complete.
Because this is still in the research stage, there is not cost to participate in the study. If you want to learn more about the study, please talk to your oncologist and visit our SageMedic Corp. website.
This trial is available at SAGE Campbell, Dublin, and Redwood City Hospitals.